Summary
The purpose of this study was to construct a pharmacokinetic/pharmacodynamic model (PK-PD model) of irbesartan in healthy Chinese adult volunteers under non-steady-state conditions and provide relevant PK/PD parameters for use in clinical practice. Thirty-six healthy Chinese adult male volunteers received 150 or 300 mg irbesartan orally in tablet form (2 groups; n=18 per group). Plasma concentrations were determined by HPLC and pharmacological effects, including effects on systolic (SBP) and diastolic blood pressure (DBP) were measured simultaneously. The experimental data were quantitatively analyzed according to the PK-PD model construct. PK/PD parameters were calculated. Blood pressure remained almost unchanged at an irbesartan dose of 150 mg under non-steady-state conditions. After a single dose of 300 mg, the pharmacokinetic profiles of irbesartan conformed to a two-compartment model. There were hysteresis loops between drug effects and plasma concentrations. The relationship between effects and effect compartment concentrations (Ce) could be represented by the sigmoid-Emax model. The Emax values for the inhibitory effects on SBP and DBP of irbesartan were 14.8+1.5 and 9.8±2.1 mmHg respectively, the EC50 values were 0.29±0.11 and 0.18±0.07 μ.ml−1, while the Keo values were 0.62±0.09 and 0.68±0.07 h−1, respectively. The PK-PD model of irbesartan was developed in healthy Chinese adult male volunteers, and may provide a more rational basis for dosage individualization.
Similar content being viewed by others
References
Waeber B. (2001 ): A review of irbesartan in antihypertensive therapy: comparison with other antihypertensive agents. Curr. Ther. Res. 62, 505–521.
Mao G.G. Chen B. Sun H. et al (2001): Relative bioavailability of irbesartan capsules in healthy volunteers. Chin. J. Clin. Pharmacol. 17, 207–209.
Vachharajani N.N. Shyu W.C. et at (1998): Oral bioavailability and disposition characteristics of irbesartan, an angiotensin antagonist, in healthy volunteers. J. Clin. Pharmacol. 38, 702–707.
Ismail Z. Triggs E.J. Smithurst B. A. et al (1989): The pharmacokinetics of amiloride hydrochlorothiazide combination in the young and elderly. Eur. J. Clin. Pharmacol. 37, 167–171.
Huang XH, Qiu FR, Xie HT, et al (2005): Pharmacokinetic and pharmacodynamic of irbesartan in renal hypertensive dogs under non-steady-state and steady-state conditions. Eur. J. Drug. Metab Pharmacokinet. 30, 121–125.
Huang XH, Qiu FR, Xie HT et al (2005): Pharmacokinetic and pharmacodynamic interaction between irbesartan and hydrochlorothiazide in renal hypertensive dogs. J. Cardiovasc. Pharmacol. 46, 863–869.
Derendorf H, Meibohm B (1999): Modeling of pharmacokinetic/ pharmacodynamic (PK/PD) relationships: concepts and perspectives. Pharm. Res. 16, 176–177.
Collum WA (1981): Simultaneous pharmacokinetic and pharmacodynamic modeling. J. Pharmacokinet. Biopharm. 9, 367–388.
Liu CX, Sun RY (1999): Experimental design and statistics of drug evaluation. Beijing: Military Medical Sciences Press. 64–66.
Meibohm B, Derendorf H (1997): Basic concepts of pharmacokinetic/ pharmacodynamic (PK/PD) modeling. Int. J. Clin. Pharmacol. Ther. 35, 401–413.
Chen ZY, Zheng QS, Sun RY (2002): Introduction to the main functions of DAS pharmacological software. Chin. J. Clin. Pharmaco. Ther. 7, 562–564.
Huang XH, Li J (2005): Drug and statistics software. Am. J. Pharm. Educ. 69, 397–398.
Yin XX, Zhang YD, Luo JP (1997): Pharmacokinetic-pharmacodynamic modeling of metoprolol stereoisomers in spontaneously hypertensive rat. Acta. Pharmacol. Sinica. 18, 104–108.
Donati F, Varin F, Ducharme J, et al (1991): Pharmacokinetics and pharmacodynamics of atraccurium obtained with arterial and venous blood samples. Clin. Pharmacol. Ther. 49, 515–522.
Fuseau E, Sheiner LB (1984): Commentary: simultaneous modeling of pharmacokinetics and pharmacodynamics with a nonparametric pharmacodynamic model. Clin. Pharmacol. Ther. 335, 733–741.
Shi SJ, Chen H, Gu SF, Zeng FD (2003): Pharmacokinetic pharmacodynamic modeling of daurisoline and dauricine in beagle dogs. Acta. Pharmacol Sin. 24, 1011–1015.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Huang, XH., Li, J., Qiu, FR. et al. PK-PD modeling of irbesartan in healthy Chinese adult volunteers under non-steady-state conditions. European Journal of Drug Metabolism and Pharmacokinetics 31, 259–264 (2006). https://doi.org/10.1007/BF03190465
Received:
Issue Date:
DOI: https://doi.org/10.1007/BF03190465